artificial tear substitute
PreclinicalSmall molecule
artificial tear substitute is one of 25 small molecule programs targeting Fuchs endothelial corneal dystrophy. It is currently in Preclinical.
2
Indications
2
Total Trials
1
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
29 competitors in Eye Disease
#DrugCompanyPhaseTrials
1Chantix
PPrism Pharmaceuticals
Approved
Neo-Synephrine
EExela Pharma Sciences, LLC.
Approved
Heparin Sodium
BBaxter Healthcare Corporation
Approved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Rapamune
PPrism Pharmaceuticals
Approved
Empaveli
Apellis PharmaceuticalsApproved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Miebo
BBausch & Lomb Incorporated
Phase 3
AZR-MD-001
AAzura Ophthalmics
Phase 3
Avastin
RochePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for artificial tear substitute. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity Hospital Dubrava